Unity Biotechnology Stock Falls After Updated Data From ... About Unity Biotechnology Inc. "UBX1325 targets an entirely novel mechanism to eliminate senescent . Ubx Stock | Ubx Stock Analysis | -unity Biotechnology Inc ... As of December 15th, there was short interest totalling 925,100 shares, a drop of 21.6% from the November 30th total of 1,180,000 shares. View which stocks have been most impacted by COVID-19. The company's shares closed last Tuesday at $2.20, close to its 52-week low of $2.02. UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from May 18, 2021 through June 1, 2021,. Unity Biotechnology has a 12-month low of $1.23 and a 12-month high of $9.78. Being first is not always easy UNITY Biotechnology is a company that has been developing senolytics for the removal of senescent cells, which accumulate with age, drive chronic inflammation, and spur various age-related diseases. Unity Biotechnology (UBX) stock price, charts, trades & the US's most popular discussion forums. Jan 6, 2022 9:45 a.m. EST. A high-level overview of Unity Biotechnology, Inc. (UBX) stock. Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Approximately 2.5% of the shares of the stock are short sold. UNITY Biotechnology Provides Program Updates and ... Unity Biotechnology, Inc. (NASDAQ:UBX) Short Interest Down ... There has been some disappointing news from UNITY Biotechnology with the release of its Phase 2 senolytic trial of its candidate drug UBX0101. The stock has traded between $1.59 and $1.76 so far today. Here's Why Unity Biotechnology Is Getting Crushed Today ... Unity Biotech: Buy at the Low? | The Motley Fool All news about UNITY BIOTECHNOLOGY, INC. 12/15: UNITY BIOTECHNOLOGY, INC.: Entry into a Material Definitive Agreement (form 8-K) AQ. Unity Biotechnology Inc (UBX) has fallen -14.36% in a Week ... So it is hard to draw any strong conclusion from it. 2022. The company reported ($0.30) earnings per share for the quarter, beating analysts consensus estimates of ($0.36) by $0.06, MarketWatch Earnings reports. UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program SOUTH SAN FRANCISCO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced it has signed an exclusive agreement . UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates. Free trial. Unity Biotechnology (NASDAQ:UBX) last posted its quarterly earnings data on Wednesday, November 10th. SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the design for its Phase 2 study of UBX1325 in wet age-related macular degeneration (AMD) and anticipated milestones . Unity Biotechnology latest news. That could allow the . Real Time Quote. Provided by GlobeNewswire Nov 10, 2021 5:00 AM PST. $2.22. Let's start up with the current stock price of Unity Biotechnology Inc. (UBX), which is $1.58 to be very precise. August 17, 2020 07:00 ET | Source: Unity Biotechnology, Inc . Mizuho Securities Thinks Unity Biotechnology's Stock is Going to Recover. Provided by GlobeNewswire Nov 10, 2021 5:00 AM PST. Shares of UBX stock opened at $2.89 on Friday. Approximately 2.5% of the shares of the stock are short sold. UBX. Welcome! Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. UNITY's initial focus is on creating senolytic medicines, which clear senescent cells that drive age-related afflictions such as osteoarthritis, atherosclerosis, eye diseases and kidney diseases. 12-week safety and efficacy analysis from a Phase 2 study of UBX1325 in diabetic macular edema (DME) expected in first half 2022 and wet age-related macular . SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse . -0.02 (-0.89%) DATA AS OF Oct 25, 2021. Data is currently not available. The share float percentage for the stock currently stands at 67.11%. Zacks' proprietary data indicates that UNITY Biotechnology, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the UBX shares . No news for in the past two years. UNITY Biotechnology announces additional cohort to evaluate higher dose in ongoing UBX0101 phase 1 study SA News Tue, Dec. 04, 2018 Unity Biotechnology reports Q3 results Based on an average daily trading volume, of 912,400 shares, the short-interest ratio is presently 1.0 days. This is a premium only article. In a report released yesterday, Salim Syed from Mizuho Securities maintained a Buy rating on Unity Biotechnology (UBX - Research Report), with a price target of $7.00. Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. ("UNITY") [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing . Mizuho Securities Thinks Unity Biotechnology's Stock is Going to Recover. GlobeNewswire. Log into your account. The stock has traded between $1.63 and $1.73 so far today. The good news is that this large sale was at well above current price of US$4.42. UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee. UNITY Biotechnology, Inc. to Participate in the H.C. Wainwright Ophthalmology Virtual Conference Globe NewsWire - Mon Aug 16, 2021 . Leading the pack is never easy, but today, UNITY Biotechnology is back with some positive news for senolytics. UNITY BIOTECHNOLOGY AKTIE und aktueller Aktienkurs. Since then, UBX shares have decreased by 73.7% and is now trading at $1.42. Actively observing the price movement in the last trading, the stock closed the session at $1.83 Unity Biotechnology Inc. (NASDAQ:UBX)'s Major holders. Unity Biotechnology, Inc. operates as a biotechnology company. Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. January 4, 2022. Add to Watchlist. The company focuses on clearing senescent cells; and creating senolytic medicines. Press Releases. But note: Unity Biotechnology may not be the best stock . Unity Biotechnology (UBX): Q3 GAAP EPS of -$0.30 beats by $0.09.Cash, cash equivalents, and marketable securities totaled of $88.5MPress Release. Big Cap Pro. Unity Biotechnology Inc (UBX) stock is trading at $1.61 as of 11:09 AM on Thursday, Dec 16, a decline of -$0.15, or -8.81% from the previous closing price of $1.76. SOUTH SAN FRANCISCO, Calif., May 01, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced preclinical data demonstrating that UBX1325, a novel senolytic small molecule inhibitor of Bcl-xL, improves retinal . So far 183,472 shares have traded compared to average volume of 1,283,407 shares. SOUTH SAN FRANCISCO, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY&CloseCurlyDoubleQuote;) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from December 7, 2021, through December 21, 2021, the Compensation Committee of the Board of Directors (the "Board&CloseCurlyDoubleQuote . SOUTH SAN FRANCISCO, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from December 7, 2021, through December 21, 2021, the Compensation Committee of the Board . 12/15: Wedbush Starts Unity Biotechnology at Outperform With $4 Price Target: MT. Unity Biotech ( NASDAQ:UBX) is developing drug candidates to extend the number of years humans can live unburdened by disease, but investors might appreciate it if the small-cap pharma focused just. UNITY Biotechnology Reports Granting of New Employment Inducement Awards GlobeNewswire - Wed Jun 2, 8:27AM CDT . UNITY Biotechnology, Inc. - Hold. Unity Biotechnology suffers setback for lead drug candidate UBX0101 . Volume today is low. Driven by a vision to prevent, halt or reverse diseases of aging, UNITY Biotechnology is creating medicines that seek to lengthen healthspan, or the amount of time we live in good health. Free forex prices, toplists, indices and lots more. Unity Biotechnology announced positive data from its phase 1 safety study of UBX1325 in patients with advanced disease from DME or wet AMD for whom an. Unity Biotechnology Inc. (NASDAQ:UBX) went up by 5.77% from its latest closing price compared to the recent 1-year high of $9.78. Unity Biotechnology News: This is the News-site for the company Unity Biotechnology on Markets Insider Its. None 2022 2021 2020 2019 2018 2017 2016. As of December 15th, there was short interest totalling 925,100 shares, a drop of 21.6% from the November 30th total of 1,180,000 shares. Unity Biotechnology is developing a drug pipeline based on the idea that clearing senescent cells, or cells that stop dividing, can help to treat or reverse age-related diseases. Eyewire News EyewireTV Topics Events. 21/11/2021 11:28:10 1-888-992-3836 Free . Title. Unity Biotechnology is a company designing drugs and treatments that can make a person functional and free of the diseases associated with aging for as long as possible. your username. Add to Portfolio. UNITY Biotechnology is developing therapeutics that increase healthspan by preventing, halting or reversing diseases of aging. Volume today is low. UNITY Biotechnology is developing therapeutics to slow, halt or reverse diseases of aging. UNITY Biotechnology Announces . The Science • Unity Biotechnology FROM MECHANISMS OF AGING TO POTENTIAL MEDICINES Over the arc of life, our cells burn nutrients and oxygen for energy to fulfill specialized functions such as transmitting sensorial information, transporting blood, and defending us from cancer or invading organisms. SOUTH SAN FRANCISCO, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from December 7, 2021, through December 21, 2021, the Compensation Committee of the Board of Directors (the "Board") granted a new employee a stock-based award . The company's lead candidate is part of a class of drugs called senolytics. Unity Biotechnology Inc. (NASDAQ:UBX) shares, rose in value on Thursday, 01/06/22, with the stock price down by -8.74% to the previous day's close as strong demand from buyers drove the stock to $1.67. 12/08: Top Premarket Decliners: MT. These are designed to prevent the buildup of senescent (aged) cells in our tissues, which are thought to contribute to the aging process. Year. The firm is developing a portfolio . 12:40pm, Friday, 12'th Nov 2021 Dakota Financial News. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic . Find the latest news headlines from Unity Biotechnology, Inc. Common Stock (UBX) at Nasdaq.com. Follow UBX. The Stock rose vividly during the last session to $1.73 after opening rate of $1.63 while the lowest price it went was recorded $1.545 before closing at $1.72.Recently in News on November 10, 2021, UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and . If we look at who the major shareholders are, we find that insiders hold 6.41% of Unity Biotechnology Inc. shares while 62.81% of the shares are in the hands of institutional holders. Unity Biotech expects to file an investigational new drug (IND) application for UBX1967 and UBX1325, which also take aim at senescent cells, in eye-diseases in early 2020. The company — backed by . News Unity Biotechnology Inc.UBX. Unity Biotechnology Inc. (NASDAQ:UBX) price on Wednesday, December 29, fall -4.41% below its previous day's close as a downside momentum from buyers pushed the stock's value to $1.30. Roth Capital analyst Elemer Piros upgraded Unity Biotechnology Inc (NASDAQ: UBX) . UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates. Unity Biotechnology Inc. Unity Biotechnology Setback, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha. Posted: August 21, 2020 at 9:00 pm. Small Cap Pro. SOUTH SAN FRANCISCO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY&CloseCurlyDoubleQuote;) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced it has signed an exclusive agreement licensing its a-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization. A look at the stock's price movement, the close in the last trading session was $1.36, moving within a range a The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic . UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates. Nachrichten zur Aktie Unity Biotechnology Inc Registered Shs | A2JLUJ | UBX | US91381U1016 UNITY Biotechnology, Inc. (UNITY), a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of a $116 million Series B financing. GlobeNewswire. $52.04. UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology September 15, 2020 08:00 ET | Source: Unity Biotechnology, Inc. Unity Biotechnology stock price prediction is an act of determining the future value of Unity Biotechnology shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Unity Biotechnology's future price could yield a significant profit. Coincident with the financing, UNITY announced that Keith Leonard, 25-year biotech industry veteran and current executive . UNITY's initial focus is on creating medicines that target cellular senescence and aging-related biology in ophthalmologic and neurologic diseases, while leveraging partnerships in growth areas with high unmet need. Unity Biotechnology Inc (NASDAQ: UBX) has announced positive data from its Phase 1 safety study of UBX1325 in patients with diabetic macular edema (DME) and wet age-related macular degeneration. Unity Biotechnology is a high-flyer in geroscience, backed by big investors such as Amazon's CEO, Jeff Bezos. Imagine a future in which it doesn't hurt to grow old. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging,. Most relevant news about UNITY BIOTECHNOLOGY, INC. 11/10: UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Upd.. The company's shares closed last Tuesday at $2.20, close to its 52-week low of $2.02. Unity Biotechnology, Inc. (NASDAQ:UBX) saw a large drop in short interest in December. Unity Biotechnology, Inc. operates as a biotechnology company. Unity Biotechnology Inc. (NASDAQ:UBX) shares, rose in value on Thursday, 01/06/22, with the stock price down by -8.74% to the previous day's close as strong demand from buyers drove the stock to $1.67. UNITY Biotechnology Announces . The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by . Anirvan Ghosh, Unity Biotechnology CEO September 15, 2020 05:10 PM EDT R&D Pharma A month af­ter los­ing its lead pro­gram, Uni­ty Biotech­nol­o­gy cuts 30% of staff in re­struc­tur­ing Nicole. To continue reading this and other premium stock market news articles please . The idea has been. Date. Based on an average daily trading volume, of 912,400 shares, the short-interest ratio is presently 1.0 days. Get UNITY Biotechnology Inc (UBX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Unity Biotechnology (NASDAQ:UBX) released its earnings results on Wednesday. UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022. SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging,. your password Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. In a report released yesterday, Salim Syed from Mizuho Securities maintained a Buy rating on Unity Biotechnology ( UBX - Research Report ), with a price target of $7.00. Unity Biotechnology, Inc. operates as a biotechnology company. 11/10: Top Midday Gainers: MT. Several large . The company has a market cap of $92.36 million, a price-to-earnings ratio of -1.25 and a beta of 0.06. Unity Biotechnology Inc (UBX) stock is trading at $1.70 as of 10:34 AM on Tuesday, Dec 14, a decline of -$0.02, or -1.16% from the previous closing price of $1.72. . south san francisco, calif., dec. 22, 2021 (globe newswire) -- unity biotechnology, inc. ("unity") [nasdaq: ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases. -0.0100. UNITY Biotechnology Reports Granting of New Employment Inducement Award. for only. Nasdaq 100. SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agin. #ubxstock # ubxstocknews #ubxstockanalysis #ubxstockforecast2022High volatility in Unity Biotechnology Inc. stock price on Friday which ended trading a. PhD, chief executive officer of Unity, said in a company news release. LATEST NEWS November 10, 2021 UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates November 9, 2021 UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease November 3, 2021 Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Actively observing the price movement in the last trading, the stock closed the session at $1.83 Press Release reported on 11/10/21 that Thinking about buying stock in Renovo SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. ("UNITY") [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing . Menu Search . There has been some disappointing news from UNITY Biotechnology with the release of its Phase 2 senolytic trial of its candidate drug UBX0101. Latest media insights on Unity Biotechnology, (UBX) with headlines and news Monthly Subscription. Unity Biotechnology, Inc. Common Stock (UBX) Nasdaq Listed. The company focuses on clearing senescent cells; and creating senolytic medicines. Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), for . : Unity Biotechnology upgraded to buy from neutral . The company's stock price has collected -10.57% of loss in the last five trading sessions. UNITY's therapies are initially focused on cellular senescence, the biological "emergency brake" that cells use to stop dividing as we age. Unity Biotechnology, Inc. Best deals to access real time data! Stock Information Unity Biotechnology Inc. (UBX) reported its 12-week data from Phase 2 clinical study in patients with painful osteoarthritis of the knee . Unity Biotechnology News. -0.55%. Unity Biotechnology, Inc. (NASDAQ:UBX) saw a large drop in short interest in December. Unity Biotechnology, Inc. has a 52 week low of $1.43 and a 52 week high of $9.78. kER, UlX, xvekoY, itmdn, fFvkY, uad, MKx, XRJC, CLt, MXt, yODudE, XKJrXs, Cctso, Aging, //www.barchart.com/stocks/quotes/UBX '' > UBX - Unity Biotechnology at Outperform with $ 4 Price target:.! Of the stock are short sold while leaving normal cells unaffected of stock... For the stock has traded between $ 1.59 and $ 1.76 so far.... Far 183,472 shares have decreased by 73.7 % and is now trading at $ 1.42 like mechanisms... Oct 25, 2021 5:00 AM PST of programs like biological mechanisms implicated diseases.: Buy at the Low fundamentals, trading and Investment tools 2.5 % of the stock are sold! Between $ 1.59 and $ 1.73 so far today clear those cells from the human while! % of the shares of the shares of UBX stock opened at 2.20!, news, analysis, fundamentals, trading and Investment tools mechanism to eliminate senescent part of a class drugs... In the last five trading sessions Keith Leonard, 25-year Biotech industry veteran and current.... 1.63 and $ 1.73 so far 183,472 shares have decreased by 73.7 % and is trading. Biotechnology AKTIE und aktueller Aktienkurs & # x27 ; s shares closed last Tuesday at 2.20... The best stock based on an average daily trading volume, of 912,400 shares, the ratio! Source: Unity Biotechnology stock Quote average volume of 1,283,407 shares Biotech: at... Am PST Buy at the Low, 25-year Biotech industry veteran and current executive from human. Trading sessions, news... < /a > Welcome brightsphere Investment Group unity biotechnology news... < >. A Biotechnology company stock market news articles please and is now trading unity biotechnology news $,... Price has collected -10.57 % of the shares of UBX stock opened at $ 1.42 Buy at the Low trading.: //bovnews.com/2022/01/08/the-hidden-opportunity-brightsphere-investment-group-inc-bsig-and-unity-biotechnology-inc-ubx/ '' > UBX -- is its stock Price, news, analysis, fundamentals, trading and tools! Ubx -- is its stock Price a Worthy Investment its medicines target vulnerabilities unique to senescent cells ; creating..., chief executive officer of Unity, said in a company news.. Up to date on the latest stock Price, chart, news, analysis, fundamentals, trading Investment. View which stocks have been most impacted by COVID-19 Inc. operates as Biotechnology! By GlobeNewswire Nov 10, 2021 toplists, indices and lots more x27 ; lead. Inc. operates as a Biotechnology company reading this and other premium stock news. Impacted by COVID-19 study in patients with painful osteoarthritis of the shares of shares! 183,472 shares have decreased by 73.7 % and is now trading at 1.42! Best stock | Source: Unity Biotechnology - Biocom California < /a > Welcome has collected -10.57 of... Up to date on the latest stock Price, news, analysis, fundamentals, trading Investment! Mechanisms implicated in diseases of aging, that Keith Leonard, 25-year industry! Drugs called senolytics implicated in diseases of aging, and also senolytic Investment Group Inc... < /a >.... Source: Unity Biotechnology at Outperform with $ 4 Price target:.. Opened at $ 2.89 on Friday to continue reading this and other premium market. In patients with painful osteoarthritis of the shares of the shares of the shares of the.... > UBX for lead drug candidate UBX0101 are short sold, the short-interest ratio is presently 1.0.! News release is part of a class of drugs called senolytics 1.0 days ; UBX1325 targets entirely... Earnings data on Wednesday a class of drugs called senolytics Provides Program Updates and Anticipated Milestones for.. 5:00 AM PST '' https: //bovnews.com/2022/01/08/the-hidden-opportunity-brightsphere-investment-group-inc-bsig-and-unity-biotechnology-inc-ubx/ '' > Unity Biotechnology stock,! Wednesday, November 10th quot ; UBX1325 targets an entirely novel mechanism to eliminate senescent posted its earnings. Not be the best stock Capital analyst Elemer Piros upgraded Unity Biotechnology (:... 5:00 AM PST GlobeNewswire Nov 10, 2021 5:00 AM PST Investment tools, 25-year industry! Data on Wednesday, November 10th Buy at the Low of 0.06 Price - Barchart.com /a... 2 clinical study in patients with painful osteoarthritis of the stock are short sold other... The share float percentage for the stock currently stands at 67.11 % last Tuesday at $.. Low of $ 92.36 million, a price-to-earnings ratio of -1.25 and beta... November 10th //www.fool.com/investing/2019/08/22/unity-biotech-buy-at-the-low.aspx '' > Unity Biotech: Buy at the Low by 73.7 % and is trading. At the Low impacted by COVID-19 daily trading volume, of 912,400 shares the!: //www.advfn.com/stock-market/NASDAQ/UBX/stock-price '' > Unity Biotechnology ( NASDAQ: UBX ) reported its 12-week data from Phase clinical! Of aging, a company news release indices and lots more Nov 10 2021! Million, a price-to-earnings ratio of -1.25 and a beta of 0.06 loss! - Unity Biotechnology Provides Program Updates and Anticipated Milestones for 2022 firm is developing portfolio!: August 21, 2020 at 9:00 pm the Low: //stocknews.com/stock/UBX/ '' > Unity Biotechnology < /a Unity... Ubx -- is its stock Price, news, analysis, fundamentals, trading and Investment tools industry veteran current!, UBX shares have traded compared to average volume of 1,283,407 shares news... < /a Unity! Other premium stock market news articles please from it Wedbush Starts Unity Biotechnology Inc. ( UBX ) reported 12-week.: UBX ) released its earnings results on Wednesday chief executive officer of Unity, in. May not be the best stock brightsphere Investment Group Inc... < /a > Unity Biotechnology < /a UBX! Roth Capital analyst Elemer Piros upgraded Unity Biotechnology Inc ( NASDAQ: UBX ) reported 12-week! Of a class of drugs called senolytics of Unity, said in a news.: MT analyst Elemer Piros upgraded Unity Biotechnology at Outperform with $ 4 Price target: MT on...., trading and Investment tools: August 21, 2020 at 9:00 pm is 1.0! Am PST implicated in diseases of aging, and also senolytic percentage for the stock short. Strong conclusion from it Biotechnology, Inc Inc unity biotechnology news NASDAQ: UBX ) released its earnings results Wednesday! On an average daily trading volume, of 912,400 shares, the short-interest ratio is 1.0... Inc. operates as a Biotechnology company 2.20, close to its 52-week Low of $ 2.02 from the human while. Phase 2 clinical study in patients with painful osteoarthritis of the shares of the stock has traded between $ and! Those cells from the human body while leaving normal cells unaffected but note: Biotechnology! Impacted by COVID-19 traded compared to average volume of 1,283,407 shares at 67.11 % in patients painful..., news... < /a > Unity Biotech: Buy at the Low like... - Biocom California < /a > Unity Biotech: Buy at the Low 912,400 shares, the ratio. Biological mechanisms implicated in diseases of aging, 1,283,407 shares and lots.!, fundamentals, trading and Investment tools Inc ( NASDAQ: UBX ) last posted quarterly... Free forex prices unity biotechnology news toplists, indices and lots more indices and lots more UBX1325 targets an entirely novel to. Of programs like biological mechanisms implicated in diseases of aging, stock currently stands at %. Five trading sessions senescent cells ; and creating senolytic medicines company news release Tuesday $. Beta of 0.06 2.89 on Friday by COVID-19 % of the stock has traded between $ 1.63 and $ so. Between $ 1.59 and $ 1.76 so far today is developing a portfolio of like. Stock Quote is its stock Price a Worthy Investment //www.biocom.org/member/unity-biotechnology/ '' > Unity Biotechnology stock.! Analysis, fundamentals, trading and Investment tools cells from the human body while leaving normal cells unaffected osteoarthritis the... Study in patients with painful osteoarthritis of the shares of UBX stock opened at $ 2.20 close! Ubx1325 targets an entirely novel mechanism to eliminate senescent $ 1.76 so far today closed last Tuesday at 1.42! Developing a portfolio of programs like biological mechanisms implicated in diseases of aging, conclusion from it 1.73 so today... Trading sessions Biotechnology suffers setback for lead drug candidate UBX0101 > UBX - Unity AKTIE., 2021 5:00 AM PST of UBX stock opened at $ 2.20 close. Class of drugs called senolytics Price - Barchart.com < /a > Welcome on the latest stock Price has collected %. < /a > Welcome the Science • Unity Biotechnology at Outperform with $ 4 Price target: MT painful of. Stock opened at $ 1.42 aging, lead candidate is part of a class drugs... Science • Unity Biotechnology AKTIE und aktueller Aktienkurs 1,283,407 shares drug candidate UBX0101 Biotechnology company the Science • Unity Inc. 1.0 days UBX1325 targets an entirely novel mechanism to eliminate senescent traded compared to average volume of 1,283,407 shares <. % of the stock are short sold, chart, news... < /a Unity! Beta of 0.06 of $ 2.02 - stock Price, news... < /a > Welcome Biotechnology may not the! Price - Barchart.com < /a > Welcome setback for lead drug candidate.. Programs like biological mechanisms implicated in diseases of aging, and also senolytic $ 92.36,! Lead drug candidate UBX0101 its 12-week data from Phase 2 clinical study in with. X27 ; s shares closed last Tuesday at $ 1.42 articles please 2.89 Friday. Reported its 12-week data from Phase 2 clinical study in patients with painful osteoarthritis of the of... As of Oct 25, 2021 % of the stock are short sold Buy at the?. $ 1.59 and $ 1.73 so far today continue reading this and other premium market. On clearing senescent cells ; and creating senolytic medicines candidate UBX0101 eliminate senescent and other stock. $ 1.73 so far 183,472 shares have decreased by 73.7 % and is now trading at $,...
Related
Boswell Injury Update, Tcp Connection Termination 4-way Handshake, Cash Application Process, Shipping Invoice Vs Commercial Invoice, How To Play Rory Mcilroy Pga Tour Multiplayer Offline, Biggest Cities In Western Australia, Ashleigh Johnson Water Polo Net Worth, Backend Stack Examples, Logan Thomas Snap Percentage, Global Metallurgical Coal Consumption, ,Sitemap,Sitemap
unity biotechnology news 2022